News | Magnetic Resonance Imaging (MRI) | July 05, 2019

Medic Vision Wins Japanese PMDA Clearance for iQMR Image Reconstruction Solution

Nagase & Co. Ltd. will distribute iQMR software to shorten MRI scan times in Japan

Medic Vision Wins Japanese PMDA Clearance for iQMR Image Reconstruction Solution

July 5, 2019 — Medic Vision Imaging Solutions announced that its 3-D iterative image reconstruction technology for shortening magnetic resonance imaging (MRI) scans, iQMR, has  been cleared by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The software will be distributed in Japan by Nagase & Co. Ltd.

The iQMR system enables short MRI protocols and enhanced image quality, to facilitate increased productivity, fewer repeating scans and improved patients’ experience. 

According to the Organisation for Economic Cooperation and Development (OECD) there are approximately 7,000 MRI scanners in Japan, second only to the U.S. market (with approximately 12,000 scanners). The number of MRI scanners per 1 million population in Japan is the highest among 27 OECD countries (51.7 versus a mean of 21.1). The number of MRI annual exams per 1,000 population in Japan is secnd among 17 OECD countries (112 versus a mean of 64).

“The growing demand of high-quality MRI scans in the Japanese healthcare system, encouraged us to introduce local hospitals and medical imaging centers [to] a solution that allows  enhanced productivity, better diagnostic outcome and experience for their patients,” said Nahomu Kameda, manager of the Medical Business Acceleration Team of Nagase & Co. Ltd. 

“We have been collaborating with Medic Vision since 2016. Its low-dose solution for CT [computed tomography] imaging, SafeCT, was cleared by PMDA in 2017, and is being practiced by hospitals and facilities in Japan since then. We anticipate that iQMR will revolutionize the Japanese MRI market with its image enhancement and fast MRI capabilities. These abilities that can be performed on any scanner, are essential to the local medical imaging centers,” continued Kameda.

Medic Vision CEO Eyal Aharon said that iQMR has allowed facilities in the U.S. and China to reduce their MRI scan time by 38 percent on average in the past year and acquire neuro MRI scans in five minutes overall. 

For more information: www.medicvision.com

Related Content

New MRI Technique Captures Brain Changes in Near-real Time

Differences in stiffness between stimulus states. Image courtesy of Patz et al.

News | Neuro Imaging | August 19, 2019
An international team of researchers developed a new magnetic resonance imaging (MRI) technique that can capture an...
ADHD Medication May Affect Brain Development in Children

Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al.

News | Neuro Imaging | August 16, 2019
A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
Synaptive Medical Launches Modus Plan With Automated Tractography Segmentation
Technology | Neuro Imaging | August 07, 2019
Synaptive Medical announced the U.S. launch and availability of Modus Plan featuring BrightMatter AutoSeg. This release...
Canon Medical Introduces Encore Orian MR Upgrade Program
News | Magnetic Resonance Imaging (MRI) | August 06, 2019
Canon Medical Systems USA Inc. is helping to provide low-cost patient care solutions for its customers with the launch...
FDA Issues Draft Guidance on Medical Device Safety in MRI Environment
News | Magnetic Resonance Imaging (MRI) | August 01, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) issued a new draft guidance titled Testing and Labeling Medical Devices for...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...